Tirzepatide review: glucose, weight, and approved uses

GIP and GLP-1 in metabolic care

Tirzepatide increases glucose-dependent insulin secretion, reduces glucagon secretion, and affects appetite and food intake. Delayed gastric emptying also matters for tolerability and some medicine interactions. The result is a combination of glucose and weight effects, not a guaranteed metabolic reset.

Mounjaro is labeled for type 2 diabetes, including a pediatric population, and the August 2026 label adds major cardiovascular-event risk reduction in adults with type 2 diabetes at high risk. Zepbound is labeled for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Those indications should remain distinct when a clinic discusses treatment and coverage.

Sources: Mounjaro prescribing information · Zepbound prescribing information

The direct obesity comparison

SURMOUNT-5 compared maximum tolerated tirzepatide 10 or 15 mg with semaglutide 1.7 or 2.4 mg in adults with obesity without type 2 diabetes. At 72 weeks, mean weight change was −20.2% versus −13.7%, respectively.

The open-label study supports a comparison of those treatments in that population. It does not compare tirzepatide with newer Wegovy HD 7.2 mg, oral Wegovy, or Foundayo, and it does not prove that every person loses more weight with tirzepatide.

Sources: SURMOUNT-5: tirzepatide compared with semaglutide for obesity

The prescription details that matter

Both branded tirzepatide products start at 2.5 mg weekly for 4 weeks before moving to 5 mg. Further increases use 2.5 mg increments after at least 4 weeks at the current dose, when appropriate. The 2.5 mg starter is not a Zepbound maintenance dose.

Tirzepatide can reduce the effectiveness of oral hormonal contraceptives. The labels advise switching to a non-oral method or adding barrier protection for 4 weeks after initiation and after each escalation. Discuss this before starting rather than discovering it at a follow-up visit.

Sources: Mounjaro prescribing information · Zepbound prescribing information

Safety before any dose change

These medicines have boxed warnings about thyroid C-cell tumors observed in rodents; whether the same risk occurs in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. This is different from saying that every thyroid condition prevents treatment.

Review severe stomach problems, previous pancreatitis, gallbladder disease, kidney problems, diabetes-related eye disease, pregnancy plans, and all medicines with your prescriber. Insulin or sulfonylureas can increase the risk of low blood sugar when combined with these treatments. Vomiting and diarrhea can cause dehydration and kidney injury.

Severe persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction require prompt medical assessment. Do not increase a dose to overcome slow weight loss or copy another person's prescription. Tell the anesthesia team about treatment before procedures because delayed gastric emptying can affect aspiration risk.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information

Two receptor targets do not define a personal outcome

GIP and GLP-1 receptor activity distinguishes tirzepatide from a medicine acting at the GLP-1 receptor alone. It does not provide a formula for predicting twice the benefit or fewer side effects. The approved labels describe glucose-dependent insulin secretion, glucagon effects, appetite and food-intake effects, and delayed gastric emptying. The clinical importance of those actions is evaluated through measured outcomes in defined populations.

For a person with type 2 diabetes, improved glycemic control may be central to the decision. For a person receiving Zepbound for obesity or obstructive sleep apnea, the relevant outcome and maintenance recommendation differ. Ask the clinician to explain the treatment objective before discussing a maximum dose. A marketing phrase such as "dual action" should not replace the product's actual evidence, contraindications, or a realistic follow-up plan.

Sources: Mounjaro prescribing information · Zepbound prescribing information

What the head-to-head advantage means in practice

SURMOUNT-5 provides a stronger basis for comparing its two treatments than unrelated placebo-controlled trials do, because participants were assigned within one study. However, it was open-label: participants and clinicians knew the treatment. It also compared particular maximum tolerated doses in adults with obesity without diabetes. The average advantage is useful evidence within those boundaries.

It does not resolve whether tirzepatide is best for a person who cannot tolerate it, cannot obtain ongoing access, or has a different clinical indication. It also does not rank newer oral medicines or Wegovy HD, which were absent from the comparison. A practical review therefore asks about efficacy, tolerability, the patient's other conditions, and sustainable care together. An injection advertised as compounded tirzepatide plus a vitamin cannot claim the trial result as evidence for that combination.

Sources: SURMOUNT-5: tirzepatide compared with semaglutide for obesity · FDA concerns with unapproved GLP-1 drugs used for weight loss

What deserves attention during the first months

The initial low dose and gradual escalation are intended to introduce treatment and address tolerability. Record the date of each increase and symptoms affecting meals or fluids. A clinician may need to review the pace and other medicines when nausea, vomiting, or diarrhea persists. Taking the injection at bedtime or changing the body site is not an established substitute for that assessment.

Review contraception before the first dose, not after a problem occurs. Also tell the clinician about insulin, sulfonylureas, planned anesthesia, and pregnancy plans. Keep a clear clinical contact route for urgent concerns; a platform's ordinary billing chat may not provide medical triage. If treatment is interrupted, share the last actual dose and reason for stopping before restarting. Familiarity with an old dose does not establish current tolerability after a long gap.

Sources: Mounjaro prescribing information · Zepbound prescribing information